Table 3.
Clinical and laboratory data
| Parameter | Training set | Test set |
|---|---|---|
| Baseline data | ||
| Median (IQR) baseline VL (log10 copies/mL) | 3.93 (2.73–4.76) | 3.96 (2.8–4.79) |
| Median (IQR) days since first treatment | 1669 (709–3010) | 1700 (741–3036) |
| Median (IQR) number of previous regimens | 4 (1–8) | 4 (1–8) |
| Treatment history | ||
| Median (IQR) number of previous drugs | 5 (3–8) | 5 (3–8) |
| NRTI experience, n (%) | 62 780 (99.7) | 3257 (99.9) |
| NNRTI experience, n (%) | 41 957 (66.7) | 2228 (68.3) |
| PI experience, n (%) | 43 227 (68.7) | 2203 (67.6) |
| Integrase inhibitor experience, n (%) | 2850 (5) | 142 (4) |
| CCR5 inhibitor experience, n (%) | 731 (1) | 30 (1) |
| New regimens | ||
| 2 NRTI + 1 PI, n (%) | 22 598 (35.9) | 1089 (33.4) |
| 2 NRTI + 1 NNRTI, n (%) | 11 658 (18.5) | 584 (17.9) |
| 3 NRTIs + 1 PI, n (%) | 4063 (6.5) | 253 (7.8) |
| 3 NRTIs, n (%) | 2511 (4.0) | 113 (3.5) |
| 3 NRTIs + 1 NNRTI, n (%) | 1609 (2.6) | 71 (2.2) |
| 2 NRTIs, n (%) | 2154 (3.4) | 109 (3.3) |
| 2 NRTIs + 1 NNRTI + 1 PI, n (%) | 1833 (2.9) | 111 (3.4) |
| 1 PI + 1 integrase inhibitor, n (%) | 0 (0) | 0 (0) |
| 4 NRTIs, n (%) | 899 (1.4) | 50 (1.5) |
| 1 NRTI + 1 NNRTI + 1 PI, n (%) | 1355 (2.2) | 61 (1.9) |
| 1 NRTI + 1 PI, n (%) | 1037 (1.6) | 74 (2.3) |
| Other, n (%) | 13 226 (21.0) | 745 (22.9) |
VL, viral load.